Rohit Singh
Assistant Professor of Medicine, Division of Hematology and Oncology
Medical Oncologist, UVM Health - University of Vermont Medical Center
Medical Oncologist, UVM Health - Central Vermont Medical Center
- MD, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences
Department of Medicine, Division of Hematology and Oncology
University of Vermont Cancer Center
Hematology and Oncology, UVM Health - University of Vermont Medical Center
Hematology and Oncology, UVM Health - Central Vermont Medical Center
BIO
Dr. Rohit Singh is a medical oncologist and faculty member at UVM. He is strongly interested in immunotherapy, lung cancer, and melanoma. Dr. Singh’s clinical work and research focus on understanding how the immune system can be harnessed to fight cancer more effectively. He places particular emphasis on the role of diet and the microbiome in shaping responses to immunotherapy. Emerging evidence suggests that gut bacteria and dietary factors can influence how well patients respond to immune-based treatments, and his work explores these interactions to optimize therapy outcomes.
Dr. Rohit Singh completed his internal medicine residency at Yale-Waterbury Hospital in Connecticut and subsequently pursued a Hematology/Oncology fellowship at the University of Vermont (UVM), where he developed expertise in medical oncology, immunotherapy, and supportive care. In addition to advancing treatment strategies, Dr. Singh is deeply committed to supportive care and the role of palliative care, ensuring that patients receive cutting-edge treatments while also having access to comprehensive, symptom-focused management throughout their cancer journey.
His published research includes work on the efficacy of immunotherapy in patients taking medications that alter the gut microbiome, prognostic classification for patients with brain metastases from solid tumors, and efforts focused on improving patient outcomes through palliative and supportive care interventions. Beyond research, Dr. Singh is actively engaged in oncology policy and advocacy and has participated in ASCO advocacy efforts to promote policies that improve access to cancer care and clinical trials. Through a combination of clinical care, research, and advocacy, he strives to enhance cancer treatment and ensure that all patients benefit from the latest advances in oncology.
Dr. Singh's postdoctoral training
- Hematology Oncology Fellow University of Vermont Medical Center
- Resident Physician, Internal Medicine Yale New Haven Medical Center (Waterbury)
- Research Assistant Yale-New Haven Hospital
- Resident Medical Officer Medanta, The Medicity Gurgaon, India
Dr. Singh's professional associations
- American Society of Clinical Oncology
- NNECOS
- American Society of Hematology
- American College of Physicians
- European Society of Medical Oncology
- International Association for the Study of Lung Cancer (IASLC)
- Society for Immunotherapy of Cancer (SITC)
Publications
Bio
Dr. Rohit Singh is a medical oncologist and faculty member at UVM. He is strongly interested in immunotherapy, lung cancer, and melanoma. Dr. Singh’s clinical work and research focus on understanding how the immune system can be harnessed to fight cancer more effectively. He places particular emphasis on the role of diet and the microbiome in shaping responses to immunotherapy. Emerging evidence suggests that gut bacteria and dietary factors can influence how well patients respond to immune-based treatments, and his work explores these interactions to optimize therapy outcomes.
Dr. Rohit Singh completed his internal medicine residency at Yale-Waterbury Hospital in Connecticut and subsequently pursued a Hematology/Oncology fellowship at the University of Vermont (UVM), where he developed expertise in medical oncology, immunotherapy, and supportive care. In addition to advancing treatment strategies, Dr. Singh is deeply committed to supportive care and the role of palliative care, ensuring that patients receive cutting-edge treatments while also having access to comprehensive, symptom-focused management throughout their cancer journey.
His published research includes work on the efficacy of immunotherapy in patients taking medications that alter the gut microbiome, prognostic classification for patients with brain metastases from solid tumors, and efforts focused on improving patient outcomes through palliative and supportive care interventions. Beyond research, Dr. Singh is actively engaged in oncology policy and advocacy and has participated in ASCO advocacy efforts to promote policies that improve access to cancer care and clinical trials. Through a combination of clinical care, research, and advocacy, he strives to enhance cancer treatment and ensure that all patients benefit from the latest advances in oncology.
Dr. Singh's postdoctoral training
- Hematology Oncology Fellow University of Vermont Medical Center
- Resident Physician, Internal Medicine Yale New Haven Medical Center (Waterbury)
- Research Assistant Yale-New Haven Hospital
- Resident Medical Officer Medanta, The Medicity Gurgaon, India
Dr. Singh's professional associations
- American Society of Clinical Oncology
- NNECOS
- American Society of Hematology
- American College of Physicians
- European Society of Medical Oncology
- International Association for the Study of Lung Cancer (IASLC)
- Society for Immunotherapy of Cancer (SITC)